Burning Rock Biotech

Burning Rock Biotech Ltd. engages in the investment of medical fields. It specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology. The firm operates through the following segments: Central Laboratory Business, In-Hospital Business and Pharma Research and Development Services. Its products and clinical applications include companion diagnostics for targeted therapy and immunotherapy, benign, malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction and tumor susceptibility tests. The company was founded by Yu Sheng Han in January 2014 and is headquartered in Guangzhou, China.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Burning Rock Biotech achieves Q1 profitability, shifts focus to in-hospital services

Burning Rock Biotech's Q1 2024 performance marked by profitability, improved efficiency, and strategic revenue transition. Challenges overcome with a focus on sustained profitability and positive breakeven targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q3 2021 Results - Earnings Call Transcript

Burning Rock Biotech (NASDAQ:BNR) reported its Q3 earnings results on Tuesday, November 16, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Recap: Burning Rock Biotech Q3 Earnings

GUANGZHOU, China, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 28, 2021 at 10:00 a.m. (local time) at the Company's Shanghai office at 5/F, Building 1, No. 138 Xinjunhuan Road, Minhang District, Shanghai and Cleary Gottlieb Steen & Hamilton (Hong Kong) at 37/F, Hysan Place, 500 Hennessy Road, Causeway Bay, Hong Kong.

Burning Rock Announces 2021 Annual General Meeting to be Held on December 28, 2021

GUANGZHOU, China, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2021.

Burning Rock Reports Third Quarter 2021 Financial Results

GUANGZHOU, China, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a collaboration with IMPACT Therapeutics where Burning Rock provides testing services in connection with IMPACT Therapeutics' development of its ATR inhibitor IMP9064, which has received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, and will begin soon in the U.S. The collaboration will be supported by Burning Rock's Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S.

Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in both US and China

GUANGZHOU, China, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company foused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2021 before the U.S. market opens on November 16, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (9:00 p.m. Hong Kong time) on the same day to discuss its financial results for the third quarter of 2021.

Burning Rock Schedules Third Quarter of 2021 Earnings Release on November 16, 2021

Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q2 2021 Results - Earnings Call Transcript

GUANGZHOU, China, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2021.

Burning Rock Reports Second Quarter 2021 Financial Results

GUANGZHOU, China, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality. The two companies will jointly develop CDx for a targeted oncology drug, Senaparib (IMP4297), a PARP inhibitor, for the treatment of prostate cancer globally, including CDx submissions to both the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China (NMPA). The global program will be supported by Burning Rock's Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S. Furthermore, the two companies will deepen collaborations in exploring and discovering new biomarkers for a pipeline of targeted drugs.

Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development

GUANGZHOU, China, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2021 before the U.S. market opens on August 31, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the second quarter of 2021.

Burning Rock Schedules Second Quarter of 2021 Earnings Release on August 31, 2021

Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q1 2021 Results - Earnings Call Transcript

GUANGZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2021.

Burning Rock Reports First Quarter 2021 Financial Results

BeiGene

Landos Biopharma

Milestone Pharmaceuticals Inc

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.

Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal

I-Mab

MSCI's addition of Pharmaron, I-Mab and Burning Rock to its China All Shares Index highlights their strong growth potential. Inclusion typically represents validation for a company's products and outlook.

Pharmaron, I-Mab And Burning Rock Get Investor Validation From MSCI

BEIJING, May 19, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced the launch of the PRESCIENT (Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT) study, the first blood-based, pan-cancer early-detection study in China using a multi-omics approach. The study is going to be led by Professor Jie He, Fellow of the Chinese Academy of Sciences and head of the China National Cancer Center, and Professor Jie Wang. Both are residing physicians at the National Cancer Center and the Cancer Hospital of the Chinese Academy of Medical Sciences.

Burning Rock Announces the Launch of China's First Prospective Pan-Cancer Multi-omics Early Detection Study

GUANGZHOU, China, May 12, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will be included in the MSCI China Index, effective after the U.S. market close on May 27, 2021. Burning Rock is the only NGS-based precision oncology company from China that has been selected in the current MSCI semi-annual index review.

Burning Rock to be Added to MSCI China Index

GUANGZHOU, China, April 28, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2021 before the U.S. market opens on May 25, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2021.

Burning Rock Schedules First Quarter of 2021 Earnings Release on May 25, 2021

GUANGZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that its liquid biopsy assay has achieved strong performance in the FDA-led Sequencing Quality Control Phase 2 (SEQC2) study, the results of which have been published on Nature Biotechnology.

Burning Rock's Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on Nature Biotechnology

Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q4 2020 Results - Earnings Call Transcript

GUANGZHOU, China, March 10, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and year ended December 31, 2020.

Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results

GUANGZHOU, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited fourth quarter and full year 2020 financial results before the U.S. market opens on March 11, 2021. Following the release, company management will host a conference call at 8:00 a.m. ET on (9:00 p.m. Hong Kong time) the same day to discuss its financial results for the fourth quarter and full year 2020.

Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March 11, 2021

Burning Rock (BNR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher

Burning Rock Biotech went public in the U.S. in June 2020. The firm provides a range of early detection and therapy selection testing services in China.

Burning Rock Biotech Expands Test Portfolio In Bid For Growth

OncoCyte

Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement with China-based Burning Rock Biotech Ltd. to bring OncoCyte's DetermaRX test for early-stage lung cancer patients to China.

News for Burning Rock Biotech Stock (BNR)